Saturday, October 12, 2019, Santa Monica, California, 8:00 AM – 4:00 PM

Year in Review: A Multitumor Regional Symposium Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers

 

Date
Saturday, October 12, 2019

Program Time
8:00 AM – 4:00 PM
Breakfast and lunch buffet to be provided

Location
Loews Santa Monica Beach Hotel
1700 Ocean Avenue
Santa Monica, CA 90401
Phone: (310) 458-6700

Meeting Room
Arcadia Ballroom (Fifth Floor)

Hotel Accommodations
A special rate of $339 (Standard King Room) has been arranged for the meeting. Please see the Location tab for additional details.

 
There is no registration fee for this event. Preregistration is advised as seating is limited.


Faculty
Acute Leukemias

Daniel A Pollyea, MD, MS
Associate Professor of Medicine
Clinical Director of Leukemia Services
Robert H Allen Endowed Chair in
Hematology Research
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado

Eytan M Stein, MD
Hematologist and Medical Oncologist
Assistant Attending Physician
Leukemia Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Breast Cancer

Matthew P Goetz, MD
Professor of Oncology and Pharmacology
Mayo Clinic
Rochester, Minnesota

Ruth M O’Regan, MD
Professor of Medicine
Chief, Division of Hematology/Oncology
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Lymphoma and Chronic Lymphocytic Leukemia

Andrew M Evens, DO, MSc
Associate Director for Clinical Services
Rutgers Cancer Institute of New Jersey
Medical Director, Oncology Service Line
RWJBarnabas Health
Director, Lymphoma Program
Division of Blood Disorders
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

Christopher R Flowers, MD, MS
Professor, Hematology and Medical Oncology
Director, Emory Lymphoma Program
Scientific Director, Winship Research Informatics
Winship Cancer Institute
Atlanta, Georgia

Ann S LaCasce, MD, MMSc
Program Director, Dana-Farber/Partners Fellowship in Hematology/Oncology
Associate Professor of Medicine
Institute Physician
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Gynecologic Cancers

Ursula Matulonis, MD
Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

David M O’Malley, MD
Professor
Medical Director, Gynecologic Oncology

Director, Clinical Research, Gynecologic Oncology
Co-Director, Gynecologic Oncology Phase I Program
ORIEN Physician Liaison for OSUCCC – James
The Ohio State University and The James
Cancer Center
Columbus, Ohio


Lung Cancer

Corey J Langer, MD
Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Naiyer Rizvi, MD
Price Family Professor of Medicine at CUMC
Columbia University Medical Center
Director, Thoracic Oncology Program
Co-Director, Immunotherapy in the
Department of Medicine
Research Director, Price Family Comprehensive Center for Chest Care at NewYork-
Presbyterian Hospital
New York, New York

Gastrointestinal Cancers

Axel Grothey, MD
Consultant Hematologist/Medical Oncologist
West Cancer Center
University of Tennessee
Memphis, Tennessee

Eileen M O’Reilly, MD
Winthrop Rockefeller Chair in Medical Oncology
Section Head, Hepatopancreaticobiliary/
Neuroendocrine Cancers
Gastrointestinal Oncology Service
Associate Director

David M Rubenstein Center for Pancreatic Cancer
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Zev Wainberg, MD, MSc
Associate Professor, Department of Medicine
Director, Early Phase Clinical Research Support
Co-Director, UCLA GI Oncology Program
Jonsson Comprehensive Cancer Center
Los Angeles, California

Genitourinary Cancers

William K Oh, MD
Chief, Division of Hematology and
Medical Oncology
Professor of Medicine and Urology
Ezra M Greenspan, MD Professor in Clinical
Cancer Therapeutics
Icahn School of Medicine at Mount Sinai
Associate Director of Clinical Research
The Tisch Cancer Institute
Mount Sinai Health System
New York, New York

David I Quinn, MBBS, PhD
Medical Director, Norris Cancer Hospital
and Clinics
Head, GU Cancer Section
Division of Cancer Medicine and Blood Diseases
USC Norris Comprehensive Cancer Center
Los Angeles, California

Moderator
Neil Love, MD
Research To Practice
Miami, Florida

 

We are pleased to once again be able to host the multitumor educational program titled Year in Review. For this daylong event an exceptional faculty panel will review many of the year’s most important new data sets and conference presentations in several distinct areas of oncology: acute leukemia, breast cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, lung cancer and lymphoma and chronic lymphocytic leukemia.

Full agenda to be announced in the late summer

Target Audience
This live activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals.

Learning Objectives
At the conclusion of this activity, participants should be able to:

  • Effectively apply the results of practice-changing clinical research to the care of patients with breast, gastrointestinal, genitourinary, gynecologic, lung and select hematologic cancers.
  • Appraise the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
  • Recall ongoing trials in breast, gastrointestinal, genitourinary, gynecologic, lung and select hematologic cancers, and refer appropriate patients for study participation.
  • Incorporate clinical characteristics, logistical factors, tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
  • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
  • Refine or validate existing cancer treatment algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators.
  • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider the implications for clinical practice.

Accreditation Statements
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CME Credit Designation Statement
Research To Practice designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit Designation Statements
This educational activity for 6.6 contact hours is provided by Research To Practice.

This activity is awarded 6.6 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This program will be submitted for ONCC/ILNA certification.

CME Credit Form
A credit form will be given to each participant at the conclusion of the activity.

CNE Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME/CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP, ACCME or the ANCC. Any off-label use as declared by the FDA will be identified.

Educational Support
This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies, Amgen Inc, Array BioPharma Inc, Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boston Biomedical Inc and Tolero Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, Genomic Health Inc, Gilead Sciences Inc, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Sanofi Genzyme, Seattle Genetics, Taiho Oncology Inc, Takeda Oncology and Tesaro, A GSK Company.

Research To Practice CME/CNE Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Loews Santa Monica Beach Hotel
1700 Ocean Avenue
Santa Monica, CA 90401
Phone: (310) 458-6700


Meeting Room
Arcadia Ballroom (Fifth Floor)

Room Reservations
A special rate of $339 (Standard King Room) has been arranged for meeting attendees. Please contact the Loews Santa Monica Beach Hotel to secure your reservations at (855) 900-4507.

  • A personal credit card will be required to secure accommodations.
  • Be sure to mention the following reference code when calling the hotel to receive the group rate: Year in Review 2019.
  • Room reservations must be made by Tuesday, September 10, 2019. A limited number of rooms are available, and we encourage you to make your reservations early.




This live activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals.

At this time registration for this educational activity is limited to practicing clinicians. For all other professionals,* we are unable to confirm seating at this time. If you would like to stand by for participation in this event, please provide your contact information by choosing the second registration option below. Should seats become available for the program, we will notify you.

There is no registration fee for this event. Preregistration is advised as seating is limited.

Registration for clinicians in practice

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Standby registration for other/industry professionals*

If you would like to stand by for participation in this event, please provide your contact information here.

Standby registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.